Search Result

Results for "

CDK-IN-6

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CDK (79) Apoptosis (12) Bcl-2 Family (1) c-Met/HGFR (1) c-Myc (2) Carbonic Anhydrase (1) Caspase (1) Cytochrome P450 (1) DNA Alkylator/Crosslinker (1) Drug Metabolite (1) E1/E2/E3 Enzyme (1) E3 Ligase Ligand-Linker Conjugates (1) EGFR (1) Epigenetic Reader Domain (2) ERK (2) Estrogen Receptor/ERR (1) FXR (2) HDAC (2) Isotope-Labeled Compounds (1) Ligands for Target Protein for PROTAC (3) MMP (2) Molecular Glues (2) NF-κB (1) p38 MAPK (1) PARP (2) PI3K (3) PROTACs (7) Raf (1) Reactive Oxygen Species (ROS) (2) Reference Standards (6) SARS-CoV (1) Ser/Thr Protease (1) STAT (2) Syk (2) Target Protein Ligand-Linker Conjugates (1) Telomerase (1) Thrombopoietin Receptor (2) VEGFR (1)
By Research Areas:	Cancer (82) Cardiovascular Disease (4) Inflammation/Immunology (4) Metabolic Disease (2)
Oligonucleotides:	Nucleoside Analogs (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: CDK Dan family AIM2 NEKs CD44

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-78428

*CDK-IN-6*	CDK	Cancer
CDK-IN-6, a class of pyrazolo[1,5-a]pyrimidine compound, is a CDK inhibitor with anticancer activities .

HY-146213

CDK4/6-IN-12	CDK	Cancer
CDK4/6-IN-12 is a potent cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. CDK4/6-IN-12 has enzymatic inhibitory activity for CDK4 and CDK6 with IC₅₀ of 592.3 nM and 3090 nM, respectively. CDK4/6-IN-12 can be used for the research of cancer .

HY-152263

*HEMTAC CDK4/6* degrader 1**	PROTACs CDK Apoptosis	Cancer
HEMTAC CDK4/6 degrader 1 is a PROTAC connected by ligands for HSP90 and *CDK4/6* with a K_d value of 35.7 μM. HEMTAC CDK4/6 degrader 1 induces CDK4/6 degradation in B16F10 melanoma cells. HEMTAC CDK4/6 degrader 1 arrests cell cycle at G0/G1 phase and induces apoptosis. HEMTAC CDK4/6 degrader 1 can be used in research of cancer . HEMTAC CDK4/6 degrader 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-112280

Crozbaciclib CDK4/6/1 INhibitor	CDK	Cancer
Crozbaciclib (CDK4/6/1 Inhibitor) is a *CDK4/6* inhibitor with IC₅₀s of 3 and 1 nM, respectively.

HY-115992

CDK4/6-IN-9	CDK	Cancer
CDK4/6-IN-9 (compound 10) is a selective *CDK4/6* inhibitor with an IC₅₀ of 905 nM for CDK6/cyclin D1. CDK4/6-IN-9 has the potential for multiple myeloma (MM) research .

HY-112418

CDK4/6-IN-18	CDK	Cancer
CDK4/6-IN-18 (Example 2BrIC) is a selective *CDK4/6* inhibitor. CDK4/6-IN-18 inhibits ionizing radiation (IR)-induced DNA damage in cells .

HY-172146

CDK4/6-IN-24	CDK	Cancer
CDK4/6-IN-24 (Compound A) is the inhibitor for *CDK4/6. CDK4/6-IN-24 exhibits board-spectrum antitumor activity that inhibits multi cancer cells with IC₅₀* of submicromolar levels .

HY-143257

CDK4/6-IN-7	CDK	Cancer
CDK4/6-IN-7 is a potent, selective and orally active *CDK4/6* inhibitor, with IC₅₀s of 1.58 and 4.09 nM, respectively. CDK4/6-IN-7 can be used for the research of breast cancer .

HY-164376A

CDK4/6-IN-21 maleate	CDK	Cancer
CDK4/6-IN-21 maleate (compound I-52) is a *CDK4/6* inhibitor with IC₅₀ values of 3.88 and 3.31 nM for CDK4 and CDK6, respectively. CDK4/6-IN-21 maleate has antitumor activity .

HY-164376

CDK4/6-IN-21	CDK	Cancer
CDK4/6-IN-21 (compound I-52) is a *CDK4/6* inhibitor with IC₅₀ values of 3.88 and 3.31 nM for CDK4 and CDK6, respectively. CDK4/6-IN-21 has antitumor activity .

HY-153704

CDK4/6-IN-17	CDK	Cancer
CDK4/6-IN-17 (compound 12) is an orally active *CDK4/6* inhibitor with IC₅₀ ranging of 10-100 nM in BE(2) cells. CDK4/6-IN-17 inhibits tumor growth in COLO205 xenograft model .

HY-168444

CDK4/6-IN-23	CDK	Cancer
CDK4/6-IN-23 (Compound 42) is a potent and selective *CDK4/6* inhibitor, with an IC₅₀ of 11 nM for CDK6. CDK4/6-IN-23 can significantly activate immune cells and promote the production of IL-3. CDK4/6-IN-23 has dual myeloprotective and immunomodulatory effects in 5-FU (HY-90006) chemotherapy mice .

HY-142076A

CDK4/6-IN-15 hydrochloride	CDK	Cancer
CDK4/6-IN-15 hydrochloride is an orally active and selective *CDK4/6* inhibitor. CDK4/6-IN-15 hydrochloride potently inhibits cancer cells growth. CDK4/6-IN-15 hydrochloride arrests cell cycle at G1 phase and suppresses retinoblastoma tumour suppressor protein (Rb) phosphorylation at S780 and E2 factor (E2F)-regulated gene expression .

HY-142076

CDK4/6-IN-15	CDK	Cancer
CDK4/6-IN-15 is an orally active and selective *CDK4/6* inhibitor. CDK4/6-IN-15 potently inhibits cancer cells growth. CDK4/6-IN-15 arrests cell cycle at G1 phase and suppresses retinoblastoma tumour suppressor protein (Rb) phosphorylation at S780 and E2 factor (E2F)-regulated gene expression .

HY-126244

CDK4/6-IN-3	CDK	Cancer
CDK4/6-IN-3 is a brain-penetrant *CDK4/CDK6* inhibitor with K_is of <0.3 nM and 2.2 nM, respectively. CDK4/6-IN-3 inhibits CDK1 with a K_i of 110 nM. CDK4/6-IN-3 can be used for the treatment of glioblastoma .

HY-115993

CDK4/6-IN-10	CDK Apoptosis	Cancer
CDK4/6-IN-10 is a potent, selective and orally active CDK4 and *CDK6* inhibitor with IC₅₀s of 22 nM and 10 nM, respectively. CDK4/6-IN-10 shows antitumor activity. CDK4/6-IN-10 has the potential for the research of Multiple myeloma (MM) .

HY-146214

CDK4/6-IN-13	CDK	Cancer
As a cdk4/6 inhibitor. Compounds 10B and 10C showed low nanomolar activity, ideal antiproliferative activity, excellent metabolic properties and acceptable pharmacokinetics on cdk4/6.

HY-138946

XY028-140	CDK PROTACs	Cancer
XY028-140 is a PROTAC connected by ligands for Cereblon and CDK. XY028-140 inhibits both CDK4/6 expression and CDK4/6 activity in cancer cells .

HY-170651

CDK4/6/HDAC-IN-1	CDK HDAC Apoptosis	Cancer
CDK4/6/HDAC-IN-1 (Compound N14) is a dual-targeting inhibitor of *CDK4/6* and HDAC (IC₅₀: CDK4 = 7.23 nM, CDK6 = 13.20 nM, HDAC1 = 55.66 nM, HDAC6 = 48.38 nM). CDK4/6/HDAC-IN-1 induces cell Apoptosis and G0/G1 phase arrest through HDAC-p21-CDK signaling pathway. CDK4/6/HDAC-IN-1 inhibits hepatocellular carcinoma .

HY-153088

CDK4/6-IN-16	CDK	Cancer
CDK4/6-IN-16 (example 195) is a potent CDK4 and *CDK6* inhibitor, with an IC₅₀ of 0.013 μM for CDK4. CDK4/6-IN-16 can be used for the research of CDK4-mediated disorders, such as cancer .

HY-112280A

Crozbaciclib fumarate	CDK	Cancer
Crozbaciclib fumarate is a *CDK4/6* inhibitor with IC₅₀s of 3 and 1 nM, respectively.

HY-175187

LO-3-63	CDK E1/E2/E3 Enzyme	Cancer
LO-3-63, a Ribociclib (HY-15777) analog bearing a truncated fumaramide handle, is a PROTAC-like *CDK4/6* degrader. LO-3-63 induces CUL4 ^DCAF16-dependent degradation of *CDK4/6* in cells .

HY-162530

CDK4/6-IN-20	CDK	Cancer
CDK4/6-IN-20 (Compound II-5) is a *CDK4/CDK6* inhibitor with IC₅₀ values of 1.9, 14.2 nM, respectively. CDK4/6-IN-20 also inhibits cell proliferation and can be used in cancer research .

HY-162529

CDK4/6-IN-19	CDK	Cancer
CDK4/6-IN-19 (Compound II-7) is a *CDK4/CDK6* inhibitor with IC₅₀ values of 0.2, 5.0 nM, respectively. CDK4/6-IN-19 also inhibits cell proliferation and can be used in cancer research .

HY-161978

CDK4/6-IN-22	CDK	Cancer
CDK4/6-IN-22 (Compound 1-A) is a CDK4 and *CDK6* dual inhibitor .

HY-151898

CDK4/6-IN-14	CDK	Cancer
CDK4/6-IN-14 is a potent and highly selective CDK4 and *CDK6* (CDK) inhibitor with IC₅₀s of 10 nM and 16 nM, respectively. CDK4/6-IN-14 exhibits more than 60-fold selectivity over CDKs 1, 2, 7, and 9, and shows high selectivity among other 205 kinases .

HY-144995

BSJ-02-162 CDK4/6-IN-11	PROTACs CDK	Cancer
CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader . CDK4/6-IN-11 consists of a thalidomide-based E3 ligase ligand (blue part) Thalidomide-NH-CH2-COOH (HY-131717), a target protein ligand (red part) Palbociclib (HY-50767), and a PROTAC linker (black part) Boc-NH-C4-Br (HY-W007803). E3 ligase ligand and linker can form Thalidomide-NH-amido-C4-Br (HY-170307).

HY-173237

CDK4/6/BRD4-IN-1	CDK Epigenetic Reader Domain	Cancer
CDK4/6/BRD4-IN-1 (B15) is an inhibitor of CDK4, *CDK6* and BRD4, with IC₅₀ values of 220 nM, 146 nM, 106 nM and 85 nM for BRD4-BD2, BRD4-BD1, CDK6 and CDK4, respectively. CDK4/6/BRD4-IN-1 (B15) can be used in the study of NSCLC (Non-Small Cell Lung Cancer). CDK4/6/BRD4-IN-1 (B15) induces cell cycle arrest and apoptosis .

HY-16297A

Abemaciclib Maximum Cited Publications 104 Publications Verification LY2835219	CDK	Cancer
Abemaciclib (LY2835219) is a selective *CDK4/6* inhibitor with IC₅₀ values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

HY-129336

Abemaciclib metabolite M20 5 Publications Verification LSN3106726	CDK	Cancer
Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective *CDK4*/6 inhibitor for the treatment of cancer .

HY-153336

CDK-IN-12	CDK	Cancer
CDK-IN-12 (Example 20) is a CDK Inhibitor. CDK-IN-12 Inhibits CDK4/6 with IC₅₀ values less than 20 nM .

HY-143258

CDK4/6-IN-8	CDK	Cancer
CDK4/6-IN-8 (Compound 7p) is a selective CDK4 and *CDK6* inhibitor with IC₅₀ values of 5.01 nM and 3.97 nM, respectively .

HY-129180

XY028-133	PROTACs CDK	Cancer
XY028-133 (example 14) is a PROTAC-based *CDK4/6* degrader with anti-tumor activity, which consists of ligands for von Hippel-Lindau and CDK .

HY-16297

Abemaciclib methanesulfonate Maximum Cited Publications 104 Publications Verification LY2835219 methanesulfonate	CDK	Cancer
Abemaciclib methanesulfonate (LY2835219 methanesulfonate) is a selective *CDK4/6* inhibitor with IC₅₀s of 2 nM and 10 nM for CDK4 and CDK6, respectively .

HY-137449

Rintodestrant G1T48	Estrogen Receptor/ERR CDK	Cancer
Rintodestrant (G1T48) is an orally active, non-steroidal and selective estrogen receptor degrader. Rintodestrant (G1T48) is also a *CDK4/6* inhibitor .

HY-16297AS

Abemaciclib-d8 LY2835219-d₈	CDK	Cancer
Abemaciclib-d₈ is the deuterium labeled Abemaciclib. Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

HY-163786

*PROTAC CDK4/6* degrader 1**	PROTACs CDK Apoptosis	Cancer
PROTAC CDK4/6 degrader 1 (Compound 7f) is a dual degrader for CDK4 and *CDK6* with DC₅₀ of 10.5 and 2.5 nM. PROTAC CDK4/6 degrader 1 inhibits the proliferation of cell Jurkat (IC₅₀ is 0.18 μM), arrests the cell cycle at G1 phase and induces apoptosis. (Pink: ligand for target protein YY173 (HY-163787); Black: linker (HY-163788); Blue: ligand for E3 ligase (HY-10984))

HY-16297AR

Abemaciclib (Standard) LY2835219 (Standard)	Reference Standards CDK	Cancer
Abemaciclib (Standard) is the analytical standard of Abemaciclib. This product is intended for research and analytical applications. Abemaciclib (LY2835219) is a selective *CDK4/6* inhibitor with IC₅₀ values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

HY-15777A

Ribociclib hydrochloride 70+ Cited Publications LEE011 hydrochloride	CDK	Cancer
Ribociclib hydrochloride (LEE011 hydrochloride) is a highly specific *CDK4/6* inhibitor with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.

HY-15777C

Ribociclib succinate hydrate 70+ Cited Publications LEE011 succINate hydrate	CDK	Cancer
Ribociclib succinate hydrate (LEE011 succinate hydrate) is a highly specific *CDK4/6* inhibitor with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.

HY-129336S

Abemaciclib metabolite M20-d8 LSN3106726-d₈	CDK	Cancer
Abemaciclib metabolite M20-d₈ is the deuterium labeled Abemaciclib metabolite M20. Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4/6 inhibitor .

HY-15777B

Ribociclib succinate 70+ Cited Publications LEE011 succINate	CDK	Cancer
Ribociclib succinate (LEE011 succinate) is a highly specific *CDK4/6* inhibitor with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.

HY-101467AR

Trilaciclib hydrochloride (Standard) G1T28 hydrochloride (Standard)	Reference Standards CDK	Cancer
Trilaciclib (hydrochloride) (Standard) is the analytical standard of Trilaciclib (hydrochloride). This product is intended for research and analytical applications. Trilaciclib hydrochloride (G1T28 hydrochloride) is a *CDK4/6* inhibitor with IC₅₀s of 1 nM and 4 nM for CDK4 and CDK6, respectively .

HY-171459

LEQ803 N-Desmethyl Ribociclib	Drug Metabolite Cytochrome P450	Cancer
LEQ803 (N-Desmethyl Ribociclib) is a drug metabolite of the CDK4/6 inhibitor Ribociclib (HY-15777), which is produced through metabolism by CYP3A4. LEQ803 has potential application value in the field of oncology .

HY-112272

Lerociclib 1 Publications Verification G1T38	CDK	Cancer
Lerociclib (G1T38) is a potent and selective inhibitor of *CDK4/6, with IC₅₀s* of 1 nM, 2 nM for CDK4/CyclinD1 and CDK6/CyclinD3, respectively.

HY-15777

Ribociclib 70+ Cited Publications LEE011	CDK	Cancer
RRibociclib (LEE011) is an ATP-competitive and orally active CDK4/6 inhibitor with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .

HY-126534A

Abemaciclib metabolite M18 hydrochloride 2 Publications Verification LSN3106729 hydrochloride	Ligands for Target Protein for PROTAC CDK	Cancer
Abemaciclib metabolite M18 (LSN3106729) hydrochloride, the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader .

HY-126534

Abemaciclib metabolite M18 2 Publications Verification LSN3106729	Ligands for Target Protein for PROTAC CDK	Cancer
Abemaciclib metabolite M18 (LSN3106729), the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 and a CRBN ligand have been used to design PROTAC CDK4/6 degrader .

HY-114339

CDK4/6-IN-2	CDK	Cancer
CDK4/6-IN-2 is a potent CDK4 and *CDK6* inhibitor extracted from patent US20180000819A1, Compound 1, has IC₅₀s of 2.7 and 16 nM for CDK4 and CDK6, respectively .

HY-131890

VH032 amide-PEG1-acid	DNA Alkylator/Crosslinker E3 Ligase Ligand-Linker Conjugates	Cancer
VH032 amide-PEG1-acid (linker 10) is a VHL-1 alkyl linker that can be used to bind *CDK4/6* ligands (PI) and degradation/destruction tags (EL) (e.g.,E3 ligase ligands) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0805

Alisol B 23-acetate 2 Publications Verification 23-Acetylalismol B; 23-O-Acetylalisol B; Alisol B monoacetate	Triterpenes Alisma plantago-aquatica Linn. Classification of Application Fields Terpenoids Source classification Other Diseases Alismataceae Plants Disease Research Fields	Apoptosis Reactive Oxygen Species (ROS) CDK MMP PARP FXR Syk
Alisol B 23-acetate is an orally active prototerpane-type triterpenoid. Alisol B 23-acetate can be isolated from Alisma orientalis. Alisol B 23-acetate induces Apoptosis, promotes ROS generation, downregulates *CDK4/6, MMP-2/9, upregulates cleaved PARP, activates FXR* and inhibits Syk. Alisol B 23-acetate has anti-inflammatory and hepatoprotective activities. Alisol B 23-acetate protects the kidney from ischemia-reperfusion injury. Alisol B 23-acetate has anticancer activity against ovarian cancer, colon cancer, lung cancer, and gastric cancer. Alisol B 23-acetate can be used in the study of atherosclerosis and allergic asthma ^[6] .

HY-N0805R

Alisol B 23-acetate (Standard) 23-Acetylalismol B (Standard); 23-O-Acetylalisol B (Standard); Alisol B monoacetate (Standard)	Triterpenes Alisma plantago-aquatica Linn. Terpenoids Source classification Alismataceae Plants	Reference Standards Apoptosis Reactive Oxygen Species (ROS) CDK MMP PARP FXR Syk
Alisol B 23-acetate (Standard) is the analytical standard of Alisol B 23-acetate (HY-N0805). This product is intended for research and analytical applications. Alisol B 23-acetate is an orally active prototerpane-type triterpenoid. Alisol B 23-acetate can be isolated from Alisma orientalis. Alisol B 23-acetate induces Apoptosis, promotes ROS generation, downregulates *CDK4/6, MMP-2/9, upregulates cleaved PARP, activates FXR* and inhibits Syk. Alisol B 23-acetate has anti-inflammatory and hepatoprotective activities. Alisol B 23-acetate protects the kidney from ischemia-reperfusion injury. Alisol B 23-acetate has anticancer activity against ovarian cancer, colon cancer, lung cancer, and gastric cancer. Alisol B 23-acetate can be used in the study of atherosclerosis and allergic asthma ^[6] .

Cat. No.	Product Name	Chemical Structure

HY-16297AS

Abemaciclib-d8
Abemaciclib-d₈ is the deuterium labeled Abemaciclib. Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

HY-129336S

Abemaciclib metabolite M20-d8
Abemaciclib metabolite M20-d₈ is the deuterium labeled Abemaciclib metabolite M20. Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4/6 inhibitor .

HY-15777S1

Ribociclib-d8
Ribociclib-d₈ is the deuterium labeled Ribociclib . Ribociclib (LEE01) is a highly specific CDK4/6 inhibitor with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .

HY-15777AS

Ribociclib-d6 hydrochloride
Ribociclib-d₆ (LEE011-d₆) hydrochloride is a deuterium labeled Ribociclib. Ribociclib is a highly specific CDK4/6 inhibitor with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .

HY-15777S

Ribociclib-d6
Ribociclib-d₆ (LEE011-d₆) is a deuterium labeled Ribociclib (HY-15777). Ribociclib is a highly specific CDK4/6 inhibitor with IC₅₀ values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .

HY-126534S

Abemaciclib metabolite M18-d8
Abemaciclib metabolite M18-d₈ is the deuterium labeled Abemaciclib metabolite M18. Abemaciclib metabolite M18 (LSN3106729), the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 and a CRBN ligand have been used to design PROTAC CDK4/6 degrader .

Cat. No.	Product Name		Classification

HY-14392

5,6-Dichlorobenzimidazole riboside 5+ Cited Publications DRB		Nucleoside Analogs
5,6-Dichlorobenzimidazole riboside (DRB) is a nucleoside analog that inhibits several carboxyl-terminal domain kinases, including casein kinase II and cell cycle-dependent kinases *(CDK)*. 5, 6-dichlorobenzimidazole riboside has antitumor activity. 5, 6-dichlorobenzimidazole riboside can induce apoptosis ^[6] .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

CDK-IN-6

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products